Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com  x.com 

These twelve stocks could dominate the next era by meeting infrastructure and consumer demand. TSMC makes AI chips; Palo Alto Networks secures cloud; GE Aerospace earns engine-service revenue; IREN builds AI cloud; Broadcom supplies chips and networking; Intuitive Surgical sells surgical robots. Strategy offers bitcoin exposure; e.l.f. Beauty serves Gen Z; Robinhood expands finance; The Trade Desk serves advertisers; Walmart adds ads and memberships; Vistra powers AI data centers. x.com  x.com  … Show more

Financing strain threatens smaller AI-related plays. Elon Musk says debt markets have nearly closed to firms without substantial non-AI-data-center revenue. Neoclouds, energy, HVAC, electronics and builders will be a much smaller field in a year; its 'guppy' plays can be shorted here toward zero. CoreWeave, IREN and Vertiv look troubled, perhaps Nebius; Ouster, Applied Digital, Ultra Clean, Cipher Digital, WhiteFiber, TeraWulf and IPG Photonics too. x.com  x.com 

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

IREN and Nebius look most attractive in AI cloud on projected 2027 revenue growth relative to their EV/revenue multiples. IREN is listed at 297% growth and 4.74x, and Nebius at 266% and 4.26x; TeraWulf and Cipher Mining have similar projected growth but multiples above 9x. x.com 

Global resistance to data centers could constrain December cloud growth despite the longer agentic AI buildout. Some estimates say roughly 120 US projects worth over $130B face delays; opposition spans the UK, EU, Australia and Malaysia too. Microsoft, Alphabet and Amazon remain favored, though guidance is at risk. CoreWeave, Nebius and IREN may bounce hardest short term but look weak longer term as funding tightens; Elon Musk expects extensive neo-cloud consolidation. x.com  x.com  x.com  x.com 

Hims & Hers could gain a massive new growth opportunity if peptide access expands after the White House completed its review of the FDA's interim policy. Six peptides, including BPC-157, TB-500 and MOTS-c, could gain expanded access; Hims is preparing treatments. The potential market is $2B-$3B. x.com 

Hims & Hers' newly previewed Peptides+ offering could add a growth vertical to its healthcare platform. Management plans access to sermorelin, glutathione and NAD+; recent regulatory developments may also open a path for BPC-157 and TB-500, subject to further conditions. Rollout and commercial opportunity remain unproven, and margins and execution are still risks. x.com 

Hardware suppliers and VC keep financing cash-hungry labs and neoclouds, making compute rental prices at CoreWeave, Nebius and IREN look artificially supported. Lab revenue growth is finally plateauing at 800% year over year after roughly tenfold equity gains across the stack over the last decade. The buildout is also crowding out the economy's appetite for debt. x.com  x.com  x.com  x.com  x.com  x.com 

IREN, Nvidia, Amazon, IonQ, Nokia, Rocket Lab, Uber and Oscar Health could become multibaggers before 2030 because they help reshape the world. Intrinsiqq's quarterly revenue charts show Nvidia up 1,254.7% over five years and IREN up 160.1% over two, while Nokia's revenue rose just 2.4% over one year. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com